Effects of recombinant human erythropoietin on antiplatelet action of aspirin and clopidogrel in healthy subjects: results of a double-blind, placebo-controlled randomized trial.

摘要: Background Recombinant human erythropoietin (rHuEpo) reduces myocardial injury in experimental ischemia and has been proposed as a cardioprotective agent for potential use acute coronary syndromes. Its safety profile clinical ischemic settings is uncertain because rHuEpo reported to increase platelet reactivity the risk of thromboembolism some disease populations. Whether prothrombotic effects mitigate antiplatelet agents used syndrome patients unknown. Methods 100, 200, 400 U/kg, or placebo was given intravenously once daily 3 consecutive days double-blind randomized trial 96 healthy subjects. A single oral dose aspirin 325 mg clopidogrel 300 immediately after last study drug. Bleeding time vitro high shear stress function assays (PFA)–100 were determined before; 5 hours; 1, 5, 7 clopidogrel. Results at doses 100 200 U/kg did not alter bleeding PFA-100 closure times any point when compared with placebo. significantly blunted post-aspirin ( P = .03) but post-clopidogrel nor PFA times. The 400-U/kg change hematocrit count drug administration .014). Conclusion Short-term up on either vivo measures attenuated increased count. Studies artery are warranted further characterize dose/safety profile.